Deal or no deal?
21 March 2024Deal or no deal? In 2023, the answer was often ‘deal’! Over US$ 84 billion worth of deals were closed…Candesic examines the phenomenon of synthetic human embryos
23 October 2023Dr Leonid Shapiro, managing partner at Candesic, and Dr Joe Taylor, principal at Candesic, examine the phenomenon of synthetic human…Candesic`s Dr Joe Taylor and Dr Leonid Shapiro published in the latest PharmaTimes
20 September 2023Candesic`s Dr Joe Taylor and Dr Leonid Shapiro discuss in PharmaTimes the significant opportunities, and the challenges, in the use…
Obesity treatment and the rise of the GLP-1 agonist
17 August 2023Candesic partner Dr Michelle Tempest and Dr Bharadwaj Chada feature on the new HealthcareMarkets UK issue. Our team investigates the…Live biotherapeutic products
12 October 2022The Boom in Bacteria! Candesic breaks down the newest potential addition to the blockbuster biologics market- live biotherapeutic products. Michelle…Pharma pricing under pressure
17 March 2019Sarah Neville in today's FT: AstraZeneca is mounting a big push into digital technologies, which includes hiring a former Nasa…Can pharma innovate like a tech giant?
1 November 2018When it comes to digital disruption in healthcare, oncology, perhaps more than any other specialty, is changing the most. Dr…Disruption has arrived for ‘big pharma’
21 December 2017Candesic's Dr Niklas Jahn and Dr Michelle Tempest suggest a silver lining for investors in the drug discovery and biotech…Personalised pharmacotherapy – who is it good for?
1 October 2017Dr Joe Taylor considers the implications of personalised pharmacotherapy for life sciences and healthcare.
Immunotherapy: A new weapon against cancer
1 June 2015Candesic's Dr Robert Watson and Dr Michelle Tempest discuss medical advances in cancer treatment. They explain medical terminology and how…
